CN108096247B - Preparation method of rosiglitazone inclusion compound - Google Patents
Preparation method of rosiglitazone inclusion compound Download PDFInfo
- Publication number
- CN108096247B CN108096247B CN201711476564.2A CN201711476564A CN108096247B CN 108096247 B CN108096247 B CN 108096247B CN 201711476564 A CN201711476564 A CN 201711476564A CN 108096247 B CN108096247 B CN 108096247B
- Authority
- CN
- China
- Prior art keywords
- rosiglitazone
- fine powder
- suspension
- stirring
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F27/00—Mixers with rotary stirring devices in fixed receptacles; Kneaders
- B01F27/05—Stirrers
- B01F27/11—Stirrers characterised by the configuration of the stirrers
- B01F27/112—Stirrers characterised by the configuration of the stirrers with arms, paddles, vanes or blades
- B01F27/1125—Stirrers characterised by the configuration of the stirrers with arms, paddles, vanes or blades with vanes or blades extending parallel or oblique to the stirrer axis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F27/00—Mixers with rotary stirring devices in fixed receptacles; Kneaders
- B01F27/05—Stirrers
- B01F27/11—Stirrers characterised by the configuration of the stirrers
- B01F27/19—Stirrers with two or more mixing elements mounted in sequence on the same axis
- B01F27/191—Stirrers with two or more mixing elements mounted in sequence on the same axis with similar elements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F27/00—Mixers with rotary stirring devices in fixed receptacles; Kneaders
- B01F27/80—Mixers with rotary stirring devices in fixed receptacles; Kneaders with stirrers rotating about a substantially vertical axis
- B01F27/90—Mixers with rotary stirring devices in fixed receptacles; Kneaders with stirrers rotating about a substantially vertical axis with paddles or arms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
- B01F35/71—Feed mechanisms
- B01F35/716—Feed mechanisms characterised by the relative arrangement of the containers for feeding or mixing the components
- B01F35/7164—Feed mechanisms characterised by the relative arrangement of the containers for feeding or mixing the components the containers being placed in parallel before contacting the contents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a preparation method of a rosiglitazone inclusion compound, which comprises the following steps: s1, adding a suspension dispersant into distilled water, and stirring to prepare a suspension; s2, adding rosiglitazone into the suspension, stirring and heating, sequentially adding methyl methacrylate, styrene and a BPO initiator, continuously heating to 80 ℃, stopping heating, stirring, gradually clathrating rosiglitazone, automatically cooling, and cooling to form fine powder; s3, washing with purified water until the water drops of the washed water are clear; s4, drying the cleaned fine powder by spin drying, and drying; s5, drying and screening fine powder of 200 meshes; s6, filling the dried and screened fine powder into a hollow hard capsule to form a capsule. The invention achieves the following beneficial effects: small side effect, high safety, convenient full play of the medicine and small difference of the drug effect among single amount of the medicine.
Description
Technical Field
The invention relates to the field of pharmacy, in particular to a preparation method of a rosiglitazone clathrate compound.
Background
The anti-diabetic effect of the rosiglitazone insulin sensitizer is verified in an animal model of type 2 diabetes (hyperglycemia or impaired glucose tolerance due to insulin resistance of a target tissue), can reduce the blood sugar of ob/ob obese mice, db/db diabetic mice and Zucker obese rats in a wandering manner, relieve the hyperinsulinemia of the mice, and delay the development of diabetes of the db/db mice and Zucker obese rats. Animal studies suggest that the anti-diabetic effect of rosiglitazone insulin sensitizers is achieved by increasing the sensitivity of liver, muscle and adipose tissue to insulin and that the gene expression of the insulin-regulated glucose transporter GLUT-4 is increased in adipose tissue. The use of the rosiglitazone insulin sensitiser does not cause hypoglycemia in model animals with type 2 diabetes or impaired glucose tolerance.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a preparation method of a rosiglitazone clathrate compound.
The purpose of the invention is realized by the following technical scheme: a preparation method of a rosiglitazone clathrate compound comprises the following steps:
s1, adding a suspension dispersant into preparation equipment filled with distilled water, and stirring to prepare a suspension, wherein the suspension dispersant accounts for 1-3% of the distilled water by mass;
s2, adding rosiglitazone into the suspension, stirring for 30min, slowly heating to 40 ℃, sequentially adding methyl methacrylate, styrene and a BPO initiator, continuously stirring and heating, wherein the stirring speed is 5000-8000 rpm, stopping heating when the temperature is raised to 80 ℃, and stirring still, so that rosiglitazone is gradually included, the components are self-heated due to reaction among each other in the stirring process, automatically cooled after the reaction is finished, and fine powder is formed after the temperature is reduced;
s3, washing the fine powder in the step S2 with purified water until water drops of the washed water are clear;
s4, spin-drying the cleaned fine powder, and drying the fine powder for 24 hours at the temperature of 80 ℃ to obtain dry fine powder;
s5, screening dry fine powder of 200 meshes from the dry fine powder in the S4 by using a filter screen;
s6, filling the hollow hard capsules with the dry fine powder to form capsules, wherein each hard capsule is filled with 40mg of the dry fine powder.
The suspension dispersant is sodium polymethacrylate.
The molecular weight of the sodium polymethacrylate is 3000-5000.
When the rosiglitazone is added to the suspension in the step S2, the rosiglitazone is mixed with the absolute ethyl alcohol and ground until the mixture is sufficiently dispersed, and the mixed rosiglitazone is pressed into the lower part, the middle part and the upper part of the suspension under the action of high pressure; the methyl methacrylate, styrene, BPO initiator were also added from the lower, middle and upper portions of the suspension.
The preparation equipment comprises a cylinder, wherein suspension liquid is filled in the cylinder, rosiglitazone feeding units are arranged at the lower part, the middle part and the upper part of one side in the cylinder, auxiliary material feeding units are arranged at the lower part, the middle part and the upper part of the other side in the cylinder, the auxiliary material feeding units are used for adding methyl methacrylate, styrene and a BPO initiator, and a stirring unit is arranged at the middle position in the cylinder;
the rosiglitazone feeding unit and the auxiliary material feeding unit have the same structure and respectively comprise a feeding body, a feeding hole of the feeding body is positioned outside the barrel, the bottom of the feeding body is positioned in the barrel, and a material distributing mechanism is detachably arranged on the bottom of the feeding body;
the material distributing mechanism comprises an installing head, one end of the installing head is installed at the bottom of the material feeding body, a plurality of branch pipes are inserted into the other end of the installing head and are communicated with the material feeding body in the axial direction, the branch pipes are bent pipes, one end, close to the installing head, of each branch pipe is a near end, the other end of each branch pipe is a far end, a plurality of through holes are formed in one side of the cylindrical surface of each branch pipe from the near end to the far end, the aperture of each through hole is gradually increased, an elastic blocking piece is fixed at each through hole, and the included angle between each elastic.
The stirring unit comprises a rotating crankshaft, and stirring blades are arranged on the crankshaft.
The invention has the following advantages: (1) the sustained-release preparation is slowly released at a constant speed in vivo, and the burst release phenomenon of a normally released preparation is avoided, so that the side effects of discomfort or damage and the like caused by short-term high drug concentration to the gastrointestinal tract are reduced, and the medication safety caused by the peak phenomenon of blood drug concentration is avoided; (2) the arrangement of the preparation equipment, particularly the structure of the branch pipe, can effectively lead the rosiglitazone to be uniformly introduced into the suspension liquid, and the dispersion is more uniform, thereby ensuring that the drug effect difference among the single amount of the drugs is small.
Drawings
FIG. 1 is a schematic structural view of the present invention;
FIG. 2 is a schematic structural view of a manifold;
in the figure: the device comprises a barrel 1, a rosiglitazone feeding unit 2, an auxiliary material feeding unit 3, a stirring unit 4, a material feeding body 5, a material distributing mechanism 6, a branch pipe 7 and an elastic baffle 8.
Detailed Description
The invention will be further described with reference to the accompanying drawings, but the scope of the invention is not limited to the following.
[ example 1 ] A method for preparing a rosiglitazone clathrate
The method comprises the following steps:
s1, adding 20g of sodium polymethacrylate into 1000ml of distilled water, fully stirring to prepare a suspension, wherein the stirring speed is 3000 r/min, the temperature is 35-40 ℃, the stirring time is 30-50 min, and the sodium polymethacrylate is completely dispersed;
s2, mixing and grinding 50g of commercially available rosiglitazone and absolute ethyl alcohol according to a mass ratio of 1:2 for 30min, adding the ground rosiglitazone into the suspension from the lower part, the middle part and the upper part under high pressure, wherein the suspension is in a stirring state when being added, the stirring speed is 5000-6000 r/min, the temperature of the suspension after being added is gradually increased to 80 ℃ so as to remove the absolute ethyl alcohol, the suspension is stopped to be heated after being increased to 80 ℃ and is naturally cooled, the rotating speed is unchanged, the rotating speed is increased to 7000-8000 r/min after being cooled to 40 ℃, 230g of methyl methacrylate, 200g of styrene and 3g of benzoyl peroxide are sequentially added at the positions of the lower part, the middle part and the upper part, the temperature is slowly increased to 80 ℃, the temperature is naturally increased but the stirring is continued, and the temperature is reduced to room temperature to form fine powder;
s3, washing the fine powder in the step S2 with purified water until the water drops of the washed water are clear;
s4, spin-drying the cleaned fine powder, and drying the fine powder for 24 hours at the temperature of 80 ℃ to obtain dry fine powder;
s5, screening dry fine powder of 200 meshes from the dry fine powder in the S4 by using a filter screen;
s6, filling the hollow hard capsules with the dry fine powder to form capsules, wherein each hard capsule is filled with 40mg of the dry fine powder.
In this example, the weight of the 200 mesh dry fine powder obtained in step S5 was 392g, and the yield was 81.2%.
Taking the preparation in the step S6, and measuring the dissolution amount of the rosiglitazone by using a rosiglitazone tablet dissolution measuring method, wherein the measuring method comprises the following steps: taking 0.5g of the preparation, and during measurement, according to 2015 version Chinese pharmacopoeia dissolution method (general rule 0931 second method), taking 500ml of hydrochloric acid solution (9 ml of concentrated hydrochloric acid is returned to purified water to 1000ml) as a dissolution medium, rotating at 50 revolutions per minute, operating according to the method, and taking the solution to filter when 0.5h, 1h, 2h, 3h, 5h, 7h, 9h, 11h and 12h are carried out, and taking the subsequent filtrate as a sample solution; taking another appropriate amount of reference substance of rosiglitazone hydrochloride, precisely weighing, adding hydrochloric acid solution (9 ml of concentrated hydrochloric acid is returned to purified water to 1000ml) to dissolve and quantitatively dilute to prepare solution containing about 2ug (1mg specification) or 8ug (4mg specification) of rosiglitazone in each 1ml, using the solution as reference substance solution, measuring according to the method under the content measurement item, and calculating the dissolution amount of each tablet, which is detailed in table 1.
TABLE 1
| Time (h) | 0.5 | 1 | 2 | 3 | 5 | 7 | 9 | 11 | 12 |
| Dissolved amount (mg) | 3.51 | 8.15 | 13.22 | 21.17 | 28.39 | 35.71 | 42.87 | 45.02 | 44.99 |
| Ratio (%) | 7.8 | 18.1 | 29.4 | 47.0 | 63.1 | 79.3 | 95.2 | 100 | 99.9 |
Note: calculated according to the ratio, 55.02mg is the total dissolution amount
Rosiglitazone content in the preparation of this example: 45.02/500 × 100% ═ 9%, total rosiglitazone encapsulation:
392 × 9% ═ 35.3g, encapsulation: 35.3/50 × 100% ═ 70.6%.
[ example 2 ] A method for preparing a rosiglitazone clathrate
The method comprises the following steps:
s1, adding 30g of sodium polymethacrylate into 1500ml of distilled water, fully stirring to prepare a suspension, wherein the stirring speed is 3000 r/min, the temperature is 35-40 ℃, the stirring time is 30-50 min, and the sodium polymethacrylate is completely dispersed;
s2, mixing and grinding 100g of commercially available rosiglitazone and absolute ethyl alcohol according to a mass ratio of 1:2 for 30min, adding the ground rosiglitazone into the suspension from the lower part, the middle part and the upper part under high pressure, wherein the suspension is in a stirring state when being added, the stirring speed is 5000-6000 r/min, the temperature of the suspension after being added is gradually increased to 80 ℃ so as to remove the absolute ethyl alcohol, the suspension is stopped to be heated after being increased to 80 ℃ and is naturally cooled, the rotating speed is unchanged, the rotating speed is increased to 7000-8000 r/min after being cooled to 40 ℃, 230g of methyl methacrylate, 200g of styrene and 3g of benzoyl peroxide are sequentially added at the positions of the lower part, the middle part and the upper part, the temperature is slowly increased to 80 ℃, the temperature is naturally increased but the stirring is continued, and the temperature is reduced to room temperature to form fine powder;
s3, washing the fine powder in the step S2 with purified water until the water drops of the washed water are clear;
s4, spin-drying the cleaned fine powder, and drying the fine powder for 24 hours at the temperature of 80 ℃ to obtain dry fine powder;
s5, screening dry fine powder of 200 meshes from the dry fine powder in the S4 by using a filter screen;
s6, filling the hollow hard capsules with the dry fine powder to form capsules, wherein each hard capsule is filled with 40mg of the dry fine powder.
In this example, the weight of the 200 mesh dry fine powder obtained in step S5 was 436g, and the yield was 82.2%.
Taking the preparation in the step S6, and measuring the dissolution amount of the rosiglitazone by using a rosiglitazone tablet dissolution measuring method, wherein the measuring method comprises the following steps: taking 0.5g of the preparation, and during measurement, according to 2015 version Chinese pharmacopoeia dissolution method (general rule 0931 second method), taking 500ml of hydrochloric acid solution (9 ml of concentrated hydrochloric acid is returned to purified water to 1000ml) as a dissolution medium, rotating at 50 revolutions per minute, operating according to the method, and taking the solution to filter when 0.5h, 1h, 2h, 3h, 5h, 7h, 9h, 11h and 12h are carried out, and taking the subsequent filtrate as a sample solution; taking another appropriate amount of reference substance of rosiglitazone hydrochloride, precisely weighing, adding hydrochloric acid solution (9 ml of concentrated hydrochloric acid is returned to purified water to 1000ml) to dissolve and quantitatively dilute to prepare solution containing about 2ug (1mg specification) or 8ug (4mg specification) of rosiglitazone in each 1ml, using the solution as reference substance solution, measuring according to the method under the content measurement item, and calculating the dissolution amount of each tablet, which is detailed in table 2.
TABLE 2
| Time (h) | 0.5 | 1 | 2 | 3 | 5 | 7 | 9 | 11 | 12 |
| Dissolved amount (mg) | 6.73 | 15.11 | 26.10 | 40.13 | 55.77 | 71.22 | 86.42 | 91.39 | 91.31 |
| Ratio (%) | 7.4 | 16.5 | 28.6 | 43.9 | 61.0 | 77.9 | 94.2 | 100 | 99.9 |
Note: calculated according to the ratio, 55.02mg is the total dissolution amount
Rosiglitazone content in the preparation of this example: 91.31/500 × 100% ═ 18.2%, total rosiglitazone encapsulation:
436 × 18.2% ═ 79.4g, encapsulation efficiency: 79.4/100 × 100% ═ 79.4%.
In the embodiment 1 and the embodiment 2, the preparation is carried out during the feeding and stirring, the preparation equipment comprises a cylinder 1, the cylinder 1 is filled with suspension, the lower part, the middle part and the upper part of one side in the cylinder 1 are provided with rosiglitazone feeding units 2, the lower part, the middle part and the upper part of the other side in the cylinder 1 are provided with auxiliary material feeding units 3, the auxiliary material feeding units 3 are used for adding methyl methacrylate, styrene and BPO initiator, and the middle part in the cylinder 1 is provided with a stirring unit 4.
Further, the rosiglitazone feeding unit 2 and the auxiliary material feeding unit 3 have the same structure and both comprise a feeding body 5, a feeding hole of the feeding body 5 is positioned outside the barrel body 1, the bottom of the feeding body 5 is positioned in the barrel body 1, and a material distributing mechanism 6 is detachably mounted on the bottom of the feeding body 5.
Furthermore, the material distributing mechanism 6 comprises a mounting head, one end of the mounting head is mounted at the bottom of the material feeding body 5, a plurality of branch pipes 7 are inserted into the other end of the mounting head, the branch pipes 7 are communicated with the material feeding body 5, the branch pipes 7 are folding pipes, one end of each branch pipe 7 close to the mounting head is a near end, the other end of each branch pipe 7 is a far end, a plurality of through holes are formed in one side of the cylindrical surface of each branch pipe 7 from the near end to the far end, the aperture of each through hole is gradually increased, an elastic blocking piece 8 is further fixed at each through hole, and the included angle between each elastic blocking piece 8 and the cylindrical.
The stirring unit 4 comprises a rotating crankshaft, and stirring blades are arranged on the crankshaft.
Claims (6)
1. A preparation method of a rosiglitazone clathrate compound is characterized by comprising the following steps: the method comprises the following steps:
s1, adding a suspension dispersant into preparation equipment filled with distilled water, and stirring to prepare a suspension, wherein the suspension dispersant is 1% ~ 3% of the distilled water by mass;
s2, adding rosiglitazone into the suspension, stirring for 30min, slowly heating to 40 ℃, sequentially adding methyl methacrylate, styrene and a BPO initiator, continuously stirring and heating, wherein the stirring speed is 5000 r/min ~ 8000 r/min, stopping heating when the temperature is raised to 80 ℃, continuously stirring, gradually clathrating the rosiglitazone, automatically heating due to the fact that the components react with each other in the stirring process, automatically cooling after the reaction is finished, and cooling to form fine powder;
s3, washing the fine powder in the step S2 with purified water until water drops of the washed water are clear;
s4, spin-drying the cleaned fine powder, and drying the fine powder for 24 hours at the temperature of 80 ℃ to obtain dry fine powder;
s5, screening dry fine powder of 200 meshes from the dry fine powder in the S4 by using a filter screen;
s6, filling the hollow hard capsules with the dry fine powder to form capsules, wherein each hard capsule is filled with 40mg of the dry fine powder.
2. The method for preparing a rosiglitazone clathrate compound according to claim 1, characterized in that: the suspension dispersant is sodium polymethacrylate.
3. The preparation method of the rosiglitazone clathrate compound as claimed in claim 2, wherein the molecular weight of the sodium polymethacrylate is 3000 ~ 5000.
4. The method for preparing a rosiglitazone clathrate compound according to claim 3, characterized in that: when the rosiglitazone is added to the suspension in the step S2, the rosiglitazone is mixed with the absolute ethyl alcohol and ground until the mixture is sufficiently dispersed, and the mixed rosiglitazone is pressed into the lower part, the middle part and the upper part of the suspension under the action of high pressure; the methyl methacrylate, styrene, BPO initiator were also added from the lower, middle and upper portions of the suspension.
5. The preparation method of the rosiglitazone clathrate compound as claimed in any one of claims 1 ~ 4, wherein the preparation equipment comprises a barrel (1), the barrel (1) is filled with suspension, rosiglitazone feeding units (2) are respectively installed at the lower part, the middle part and the upper part of one side in the barrel (1), auxiliary material feeding units (3) are respectively arranged at the lower part, the middle part and the upper part of the other side in the barrel (1), the auxiliary material feeding units (3) are used for adding methyl methacrylate, styrene and BPO initiator, and a stirring unit (4) is arranged at the middle position in the barrel (1);
the rosiglitazone feeding unit (2) and the auxiliary material feeding unit (3) are identical in structure and respectively comprise a feeding body (5), a feeding hole of the feeding body (5) is positioned outside the barrel body (1), the bottom of the feeding body (5) is positioned in the barrel body (1), and a material distributing mechanism (6) is detachably arranged on the bottom of the feeding body (5);
the material distributing mechanism (6) comprises an installing head, one end of the installing head is installed at the bottom of the material feeding body (5), a plurality of branch pipes (7) are inserted into the other end of the installing head, the branch pipes (7) are communicated with the material feeding body (5), the branch pipes (7) are bent pipes, one ends, close to the installing head, of the branch pipes (7) are near ends, the other ends of the branch pipes are far ends, a plurality of through holes are formed in one side of the cylindrical surface of each branch pipe (7) from the near ends to the far ends, the aperture of each through hole is gradually increased, an elastic blocking piece (8) is fixed at each through hole, and the included angle between each elastic blocking piece (8) from the near ends to.
6. The method for preparing a rosiglitazone clathrate compound according to claim 5, characterized in that: the stirring unit (4) comprises a rotating crankshaft, and stirring blades are arranged on the crankshaft.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711476564.2A CN108096247B (en) | 2017-12-29 | 2017-12-29 | Preparation method of rosiglitazone inclusion compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711476564.2A CN108096247B (en) | 2017-12-29 | 2017-12-29 | Preparation method of rosiglitazone inclusion compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108096247A CN108096247A (en) | 2018-06-01 |
| CN108096247B true CN108096247B (en) | 2019-12-31 |
Family
ID=62214840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711476564.2A Active CN108096247B (en) | 2017-12-29 | 2017-12-29 | Preparation method of rosiglitazone inclusion compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108096247B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA763405A (en) * | 1967-07-18 | Speiser Peter | Process for the manufacture of pharmaceutical preparations in bead form | |
| US8921429B2 (en) * | 2010-11-23 | 2014-12-30 | Howard University | Biodegradable stealth polymeric particles fabricated using the macromonomer approach by free radical dispersion polymerization |
| CN102388862B (en) * | 2011-07-29 | 2014-01-15 | 华南农业大学 | Controlled release preparation for killing water hyacinth and preparation method of controlled release preparation |
-
2017
- 2017-12-29 CN CN201711476564.2A patent/CN108096247B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108096247A (en) | 2018-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102216458B (en) | Antisense compositions and methods of making and using same | |
| CN101574323B (en) | Migltol microcapsule tablet and preparation method thereof | |
| CN110934853A (en) | Mosapride citrate sustained-release pellet capsule and preparation method thereof | |
| CN105030802B (en) | Application of lignan compound | |
| CN101612195A (en) | A kind of polynary medicine-releasing system that contains Radix Salviae Miltiorrhizae and Radix Notoginseng | |
| CN101229225A (en) | Salvia miltiorrhiza total phenolic acid gastric stasis preparation | |
| CN108096247B (en) | Preparation method of rosiglitazone inclusion compound | |
| US9023388B2 (en) | Formulation of silibinin with high efficacy and prolonged action and the preparation method thereof | |
| CN104873473A (en) | Potassium chloride sustained-release tablet and preparation method thereof | |
| CN102727447A (en) | Florfenicol controlled release preparation and preparation method thereof | |
| CN111494328B (en) | Osmotic pump tablet containing acarbose and dapagliflozin and preparation method thereof | |
| CN105534935B (en) | Pantoprazole microplate, preparation method, multiple unit type Pantoprazole enteric sustained-release preparation and preparation method thereof | |
| CN102258496B (en) | Pyridostigmine bromide sustained-release tablets and preparation method thereof | |
| CN105919979A (en) | Tetrodotoxin enteric-coated and sustained-release pellet, and preparation method and application thereof | |
| BR112014032578B1 (en) | DRUG FORM FOR RELEASE OF ACTIVE INGREDIENTS, ITS PRODUCTION AND USE METHOD | |
| CN108066313B (en) | Preparation method of metformin hydrochloride clathrate | |
| CN104906077B (en) | A kind of fenofibrate choline salt controlled release preparation with two-phase drug release feature and preparation method thereof | |
| CN1785239A (en) | Compounding Salvia Miltiorrhiza delayed-release prepn. and its preparing method | |
| CN101961324A (en) | Prescription and preparation method of etofbrate release capsules | |
| CN115671054A (en) | Mannitol pellet core and preparation method and application thereof | |
| CN103301089A (en) | Famciclovir capsule preparation and preparation method thereof | |
| CN108553416A (en) | A kind of sustained release mixed suspension preparation and preparation method thereof containing levodopa and benserazide hydrochloride | |
| CN104367555B (en) | Bioadhesion type hollow microsphere and preparation method thereof | |
| CN101683340A (en) | Sustained-release preparation of compound metformin hydrochloride rosiglitazone and preparation method thereof | |
| CN117017921B (en) | Ginsenoside liposome and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Qiu Yin Inventor after: Liu Shuang Inventor after: Wang Ying Inventor after: Chen Qin Inventor after: Li Fafei Inventor after: Xia Wenhong Inventor after: Shen Hua Inventor before: Qiu Yin Inventor before: Liu Shuang Inventor before: Wang Ying Inventor before: Chen Qin Inventor before: Li Fafei Inventor before: Xia Wenhong |